CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy

Writing Group Chair Naveen Pereira, MD and Vice Chair Sharon Cresci, MD discuss a new scientific statement from the American Heart Association.
View supporting materials:
professional.heart.org/en/sci...

[@alexandraczepula8391]

Dear all, do intermediate metabolizers of the enzyme also need to switch to ticagrelor or prasugrel even when using cilostazol? This AHA document contains studies that mention cilostazol. This information was not clear to me. Grateful.